News | Proton Therapy | January 28, 2019

Southern Asia's First Proton Therapy Center Begins Treatments

First patient at Apollo Proton Cancer Centre in Chennai, India, treated for prostate cancer

Southern Asia's First Proton Therapy Center Begins Treatments

January 28, 2019 — IBA (Ion Beam Applications SA) announced the opening of the Apollo Proton Cancer Centre in Chennai, India, and the first treatment of a patient with proton therapy in Southern Asia.

The medical team from the Apollo Proton Cancer Centre in Chennai successfully treated the patient with the IBA Proteus Plus multi-room proton therapy solution on Jan. 2, 2019. The patient was treated for prostate cancer and proton therapy was used to maximize preservation of the surrounding healthy tissues.

Proton therapy has already benefited to more than 180,000 patients treated worldwide. This number is expected to double over the next five years, supported by expert opinion and clinical experience. In recent years, this has led centers in Japan, Korea, the Netherlands, Germany and the U.S. to increase the number of indications treated with proton therapy.

Proton therapy offers many potential benefits to the patients, such as:

  • The potential increase in therapeutic dose within the tumor to raise the probability of eradicating it;
  • The possibility of preserving healthy tissues around the tumor with a consequent reduction in side effects; and
  • A reduction in the overall dose delivered to the patient, thus reducing the risk of a second cancer.

For more information: www.iba-worldwide.com

Related Content

MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system
News | Proton Therapy | October 07, 2019
ProTom International received 510(k) clearance from the U.S.
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the
eBook on Hypofractionation in the Age of Value-based Care

eBook on Hypofractionation in the Age of Value-based Care

Sponsored Content | Case Study | Radiation Therapy | September 30, 2019
Hypofractionated and ultrahypofractionated radiation therapy — increasing dose per fraction to enable significantly f